Endocrine Abstracts

Introduction: Tolvaptan is the only V2-receptor antagonist authorized for use in Europe in patients with SIADH. Its initiation requires hospitalization. Our goal was to analyze the safety and efficacy of tolvaptan started in a Hospital Day-Ward.Material and methods: Retrospective descriptive study of 33 ambulatory patients with mild/moderate SIADH-induced chronic sustained hyponatremia initiating tolvaptan therapy in the Day-Ward of a tertiary center ove...

Introduction: Obesity and its comorbidities, specially type 2 diabetes (T2D), are a major public health problem. The disappointing result of dietary treatment and the scarce of drugs have led to increased bariatric surgery (BS) as the most efficient therapeutic option. However, not all obese patients with T2D who undergo BS achieve diabetes remission.Objective: To develop a genetic scoring system for predicting T2D remission following BS. 2) To compare o...